MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Repeat Emergency Department Visits Among Patients With Asthma and COPD

Not Applicable
Terminated
Conditions
Asthma
COPD
Interventions
Drug: beclamethasone dipropionate
Drug: albuterol
Drug: Prednisone
First Posted Date
2015-07-16
Last Posted Date
2019-06-04
Lead Sponsor
State University of New York at Buffalo
Target Recruit Count
6
Registration Number
NCT02499887
Locations
🇺🇸

Erie County Medical Center, Buffalo, New York, United States

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Phase 2
Completed
Conditions
Asthma
Efficacy
Safety
Interventions
Drug: 250 µg AZD7594 once daily
Drug: 800 μg AZD7594 once daily
Drug: 58 µg AZD7594 once daily
Drug: Placebo once daily
Drug: Salbutamol
First Posted Date
2015-06-24
Last Posted Date
2018-02-15
Lead Sponsor
AstraZeneca
Target Recruit Count
54
Registration Number
NCT02479412
Locations
🇩🇪

Research Site, Wiesbaden, Germany

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: RPL554
Drug: Placebo
Drug: Salbutamol
First Posted Date
2015-04-27
Last Posted Date
2016-09-09
Lead Sponsor
Verona Pharma plc
Target Recruit Count
29
Registration Number
NCT02427165
Locations
🇸🇪

Skane University Hospital, Lund, Sweden

🇬🇧

Celerion, Belfast, United Kingdom

Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease

Phase 4
Completed
Conditions
Pompe Disease
Interventions
First Posted Date
2015-04-01
Last Posted Date
2016-09-20
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
14
Registration Number
NCT02405598
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

Phase 4
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: NVA237
Drug: Placebo
Drug: Salbutamol
First Posted Date
2015-02-25
Last Posted Date
2019-08-09
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
776
Registration Number
NCT02371629
Locations
🇸🇪

Novartis Investigative Site, Lund, Sweden

Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With COPD

Not Applicable
Completed
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
First Posted Date
2014-11-20
Last Posted Date
2015-07-28
Lead Sponsor
Zhujiang Hospital
Target Recruit Count
22
Registration Number
NCT02296047
Locations
🇨🇳

Zhujiang Hospital,Southern Medical Universtiy, Guangzhou, Guangdong, China

Bronchodilator Test in Mechanical Ventilated Chronic Obstructive Pulmonary Disease Patients

Not Applicable
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2014-08-18
Last Posted Date
2014-08-18
Lead Sponsor
Beijing Chao Yang Hospital
Target Recruit Count
120
Registration Number
NCT02218398
Locations
🇨🇳

Respiratory Intensive Care Unit, Beijing Chaoyang Hospital, Beijing, Beijing, China

Helium-3 MRI Imaging Study in COPD

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Device: He-3 MRI
Drug: Salbutamol
Drug: Ipratropium
Device: MRI
First Posted Date
2014-08-04
Last Posted Date
2017-06-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
11
Registration Number
NCT02207452
Locations
🇬🇧

GSK Investigational Site, Sheffield, United Kingdom

Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02182713
© Copyright 2025. All Rights Reserved by MedPath